Enlicitide

What is Enlicitide?

Enlicitide (development code MK-0616, INN enlicitide decanoate, brand name Lipfendra) is Merck's oral macrocyclic peptide that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), the protein that promotes LDL receptor degradation in hepatocytes. The FDA approved it on July 16, 2026 under NDA 220848 as the first oral PCSK9 inhibitor — indicated, in the label's own words, as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). PCSK9 inhibition was already transformative through the injectable monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent), both validated by cardiovascular outcomes trials but limited by injection burden. Enlicitide delivers comparable LDL-C reductions as a once-daily tablet, which is the entire point of the molecule. The approval rests on two pivotal Phase 3 trials, both using 20 mg once daily for 52 weeks. CORALreef Lipids (NEJM, PMID 41879224, n=2,909) cut LDL-C by 57.1% versus a 3.0% rise on placebo at week 24 — a between-group difference of 55.8 percentage points. CORALreef HeFH (JAMA, PMID 41206969, n=303) cut it by 58.2% versus a 2.6% rise, a difference of 59.4 points, and also lowered lipoprotein(a) by a median 24.7%. Those two trials plus CORALreef AddOn randomised about 3,500 patients between them; the much larger cardiovascular outcomes trial, CORALreef Outcomes (NCT06008756, n=14,550), is still running and does not finish until late 2029. The medicinal chemistry came out of mRNA display screening (Johns et al., Circulation 2023, PMID 37125593), was detailed by Josien and colleagues (J Med Chem 2026, PMID 42201324), and the biocatalytic manufacturing cascade that made tonne-scale production feasible was reported in Science by Klapars and colleagues (PMID 42096573).

What Enlicitide Is Investigated For

Enlicitide is Merck's oral macrocyclic peptide PCSK9 inhibitor, sold as Lipfendra — the first of its class to reach FDA approval, on July 16, 2026. The label indication is an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. Five Phase 3 CORALreef trials exist and all used 20 mg once daily: Lipids (NCT05952856), HeFH (NCT05952869), AddOn (NCT06450366), an open-label Extension (NCT06492291) and the still-running Outcomes CVOT (NCT06008756). There is no CORALreef trial in statin intolerance. The headline numbers are consistent across both pivotal trials. CORALreef Lipids (n=2,909) reduced LDL-C by 57.1% at week 24 versus a 3.0% rise on placebo — a difference of 55.8 percentage points. CORALreef HeFH (n=303) reduced it by 58.2% versus a 2.6% rise, a difference of 59.4 points, and also lowered ApoB by 49.1 points and lipoprotein(a) by a median 27.5 points against placebo. A 2026 meta-analysis of three placebo-controlled trials in 3,593 participants (PMID 42867105) pools the effect at a 56.19% mean difference. Against the existing oral non-statins, enlicitide produced greater reductions in LDL-C, ApoB and non-HDL-C (Catapano et al., JACC 2026, PMID 42017875). The honest caveats are specific. First, no outcomes data: CORALreef Outcomes enrolls 14,550 patients but does not reach primary completion until November 2029, so nobody yet knows whether enlicitide prevents heart attacks and strokes, and Merck says so explicitly. Every clinical decision today rests on LDL-C as a surrogate. Second, the drug is genuinely fussy to take — oral bioavailability is only about 1%, achieved with the permeation enhancer sodium caprate, and taking the tablet after a meal rather than before cuts exposure roughly in half. Third, long-term safety of macrocyclic peptide PCSK9 inhibition beyond the 52-week trials is still accruing.

History & Discovery

PCSK9 was identified as a therapeutic target in the early 2000s following population genetics work showing that loss-of-function PCSK9 variants are associated with substantially lower LDL-C and reduced cardiovascular events. The monoclonal antibody PCSK9 inhibitors evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron) reached FDA approval in 2015 with the FOURIER (2017) and ODYSSEY OUTCOMES (2018) trials establishing cardiovascular outcomes benefit. Inclisiran (Leqvio, Novartis), an siRNA against PCSK9, followed in 2021 with twice-yearly dosing. The oral PCSK9 inhibitor challenge — historically considered intractable because PCSK9 and the LDL receptor meet across a broad flat protein-protein interface with no small-molecule pocket, and because peptides large enough to block it do not survive the gut — was tackled by Merck's macrocyclic peptide platform. The starting point was not medicinal chemistry in the classical sense but mRNA display: a screen of enormous peptide libraries that identified lead chemical matter, which structure-based design then optimised into MK-0616 with 5 pM affinity for PCSK9 (Johns et al., Circulation 2023, PMID 37125593). Josien and colleagues later documented the full design campaign (J Med Chem 2026, PMID 42201324; corrected at PMID 42720501). Oral delivery was solved separately, by formulating the tablet with the permeation enhancer sodium caprate rather than by modifying the peptide itself. Phase 1 established the dose that would carry through the entire programme: 14 days of 20 mg once daily produced a maximum 61% LDL-C reduction in statin-treated participants. A Phase 2b trial (PMID 36889610) tested 6, 12, 18 and 30 mg over 8 weeks, giving placebo-adjusted reductions of 41.2%, 55.7%, 59.1% and 60.9% — a dose-response that flattened above the mid range and settled the choice of 20 mg for Phase 3. The CORALreef programme began enrolling in 2023 and reported in 2025 and 2026: Lipids, HeFH and AddOn on efficacy, with the Extension and the Outcomes CVOT still running. On July 16, 2026 the FDA approved enlicitide as Lipfendra under NDA 220848, a Type 1 New Molecular Entity granted priority review — the first oral PCSK9 inhibitor and the highest-profile proof that macrocyclic peptides can be made into real oral drugs (Anderer, JAMA 2026, PMID 42536382; Brunham, JACC editorial, PMID 42233923; Sun et al., Drug Discov Ther 2026, PMID 42604807).

How It Works

Enlicitide is a pill that blocks PCSK9, a protein that destroys the liver's LDL receptors. By blocking PCSK9, more LDL receptors stay on liver cells, pulling more bad cholesterol out of the blood and lowering LDL-C levels by half or more. The mechanism is identical to the injectable PCSK9 antibodies (Repatha, Praluent) but delivered as a daily oral pill.

PCSK9 binds the LDL receptor (LDLR) at the hepatocyte cell surface and targets the LDLR-PCSK9 complex for lysosomal degradation, preventing LDL receptor recycling and reducing the liver's capacity to clear circulating LDL. Inhibiting PCSK9 — whether by monoclonal antibody (evolocumab, alirocumab), siRNA (inclisiran), or now macrocyclic peptide (enlicitide) — preserves LDL receptor recycling, increases hepatic LDL-C uptake, and reduces serum LDL-C substantially. The label states the mechanism plainly: by inhibiting the binding of PCSK9 to LDLR, enlicitide increases the number of LDL receptors available to clear LDL-C. Enlicitide is a macrocyclic peptide that binds PCSK9 at its LDLR-binding interface with an affinity of roughly 5 pM, identified through mRNA display screening and then optimised by structure-based design (Johns et al., Circulation 2023, PMID 37125593). The constrained ring structure is what lets it survive the gut at all. It is worth being precise about the decanoate, because it is widely misdescribed: enlicitide decanoate is a salt, not a prodrug — the tablet contains 20 mg of enlicitide equivalent to 22.21 mg of the decanoate form — and nothing is cleaved off after absorption. What actually drives absorption is a separate excipient, the permeation enhancer sodium caprate, formulated into the tablet. Even so, oral bioavailability is only about 1%, which is why food timing matters so much and why the tablet is a fixed 20 mg rather than a titratable dose. Pharmacokinetically, enlicitide reaches peak concentration within 0.5 to 1 hour, attains steady state in about 7 days with an accumulation ratio of 1.42, and shows concentration-dependent plasma protein binding that falls from 93% to 32% across the clinical range. A 2026 Science paper by Klapars and colleagues (PMID 42096573) described the biocatalytic enzyme cascade that made manufacturing this molecule practical at commercial scale — a genuine constraint for a 1%-bioavailable daily oral peptide, since every tablet must carry far more material than reaches the target.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Enlicitide:

• 01Cardiovascular outcomes are the central unknown. CORALreef Outcomes (NCT06008756) randomizes 14,550 patients to enlicitide 20 mg or placebo with a coronary-heart-disease-death-based MACE-plus primary endpoint, but it is active-not-recruiting with primary completion estimated November 29, 2029 and study completion November 2031. The commonly repeated 2027 readout date is wrong by roughly two years. Until then, enlicitide's benefit on events is inferred from LDL-C, exactly as inclisiran's was.
• 02Head-to-head comparison against the injectable PCSK9 antibodies has never been run — not on LDL-C, not on outcomes, not on adherence. Patients taking another PCSK9 inhibitor were excluded from the pivotal trial, so even indirect within-trial comparison is unavailable.
• 03Real-world adherence to the fasting requirement is completely uncharacterized, and it is the gap most likely to matter in practice. Dosing after a meal halves exposure, so a population taking the tablet with breakfast would show systematically blunted LDL-C response that looks like non-response rather than mistiming. No study has measured how often this happens outside a trial.
• 04Long-term safety beyond 52 weeks — the longest controlled exposure to date — will only accumulate through post-marketing pharmacovigilance and the open-label Extension study (NCT06492291, n=3,000, primary completion October 2028).
• 05Pediatric use is being studied but is a decade from answering. NCT07058077 is recruiting children and adolescents in a Phase 2/3 design, with primary completion estimated December 2033. Familial hypercholesterolemia is precisely the pediatric population where early LDL-C control matters most.
• 06Use in pregnancy and lactation has not been studied in humans; the label directs discontinuation when pregnancy is recognised, and animal data showed no embryofetal harm at large exposure multiples, but that is not the same as human evidence.
• 07Lipoprotein(a) lowering of roughly 25% was a consistent secondary finding, but no trial has tested whether that specific effect translates into clinical benefit. A Phase 2 trial combining enlicitide with MK-7262 in patients with high Lp(a) (NCT07614984) is now recruiting.

Forms & Administration

One 20 mg film-coated tablet by mouth, once daily — a single strength, with no titration. Approved by the FDA on July 16, 2026 as Lipfendra (NDA 220848), the first oral PCSK9 inhibitor. The administration instructions are strict and are part of the drug working: take it on an empty stomach in the morning with water, black coffee, or plain tea only, swallow it whole without splitting, crushing or chewing, and wait at least 30 minutes before any food or other drink. Dosing 30 minutes after a meal instead reduces AUC by 48% and peak concentration by 50%. LDL-C response can be measured as early as 4 weeks after starting. All lipid-lowering therapy should be directed by a clinician.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Enlicitide (Lipfendra) is an FDA-approved prescription medicine, approved July 16, 2026. It is not a research peptide and not available through compounding or research-chemical channels. Treatment of hypercholesterolemia requires individualized assessment by a primary care clinician, lipid specialist or cardiologist. This page is educational reference, not treatment direction, and the dosing described is the approved label's — not advice to start, stop or change therapy.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Enlicitide Is NOT For

Drug & Supplement Interactions

The approved label is unusually clean here, and it is backed by evidence rather than silence: Merck ran a dedicated programme of individual interaction studies and the label states that no clinically meaningful drug interactions have been observed. Specifically, Lipfendra did not affect exposure to lithium, levothyroxine, digoxin, warfarin, atorvastatin, alendronate, lisinopril, or oral semaglutide tablets. In the other direction, neither atorvastatin nor oral semaglutide affected exposure to enlicitide. Based on in vitro work, enlicitide has very low interaction potential through cytochrome P450 enzymes or drug transporters at the therapeutic dose, and the label says plainly that it can be taken with other medications. The oral-semaglutide result deserves a note, because both products solve the same problem in the same way and might have been expected to collide: semaglutide tablets use salcaprozate sodium as their absorption enhancer and Lipfendra uses sodium caprate, yet neither interfered with the other. The real-world interaction is about timing, not pharmacology. Enlicitide requires a 30-minute fast after dosing, so other morning medications — and anything taken with food — are usually moved later in the day. For the intended clinical use, concurrent statin therapy is the expected pattern and is mechanistically complementary; ezetimibe combinations were studied in CORALreef AddOn. Combining enlicitide with an injectable PCSK9 antibody or with inclisiran is not an established strategy, and patients on another PCSK9 inhibitor were excluded from the pivotal trial.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions